- Home
- ARR vs CLDX Comparison
ARR vs CLDX Comparison
Compare ARR & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARR
- CLDX
- Stock Information
- Founded
- ARR 2008
- CLDX N/A
- Country
- ARR United States
- CLDX United States
- Employees
- ARR N/A
- CLDX N/A
- Industry
- ARR Real Estate Investment Trusts
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ARR Real Estate
- CLDX Health Care
- Exchange
- ARR Nasdaq
- CLDX Nasdaq
- Market Cap
- ARR 1.4B
- CLDX 1.3B
- IPO Year
- ARR N/A
- CLDX 2008
- Fundamental
- Price
- ARR $16.47
- CLDX $20.50
- Analyst Decision
- ARR Hold
- CLDX Buy
- Analyst Count
- ARR 5
- CLDX 9
- Target Price
- ARR $21.00
- CLDX $50.00
- AVG Volume (30 Days)
- ARR 2.0M
- CLDX 1.2M
- Earning Date
- ARR 07-23-2025
- CLDX 08-07-2025
- Dividend Yield
- ARR 17.50%
- CLDX N/A
- EPS Growth
- ARR N/A
- CLDX N/A
- EPS
- ARR N/A
- CLDX N/A
- Revenue
- ARR $44,778,000.00
- CLDX $7,559,000.00
- Revenue This Year
- ARR $532.77
- CLDX N/A
- Revenue Next Year
- ARR $15.62
- CLDX N/A
- P/E Ratio
- ARR N/A
- CLDX N/A
- Revenue Growth
- ARR 41.14
- CLDX 24.49
- 52 Week Low
- ARR $13.18
- CLDX $14.40
- 52 Week High
- ARR $21.93
- CLDX $47.00
- Technical
- Relative Strength Index (RSI)
- ARR 50.17
- CLDX 52.11
- Support Level
- ARR $16.16
- CLDX $19.77
- Resistance Level
- ARR $16.93
- CLDX $24.03
- Average True Range (ATR)
- ARR 0.26
- CLDX 1.31
- MACD
- ARR -0.02
- CLDX -0.00
- Stochastic Oscillator
- ARR 50.53
- CLDX 26.15
About ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.